论文部分内容阅读
目的:探讨凋亡抑制蛋白Livin与人类白细胞抗原(HLA)I类分子在人类肾脏透明细胞癌(clear cell renal cell carcinoma,ccRCC)中的表达及其临床意义。方法:选择哈尔滨医科大学附属第一医院2007年12月至2011年12月收治的拟行肾癌根治术的患者80例,应用免疫组织化学方法检测80例ccRCC组织与10例癌旁正常肾组织中Livin及HLA-I类分子的表达,并分析其与患者临床病理特征之间的关系。结果:10例癌旁正常肾组织中均未见Livin的阳性表达,而HLA-I类分子的阳性表达率为100%。ccRCC组织中,Livin的阳性表达率及HLA I类分子表达下调百分率分别为41(51.25%)例和48(60.00%)例,Livin的阳性表达率与正常组相比差异有统计学差异(P<0.05)。ccRCC组织中Livin的阳性表达率与淋巴结转移、组织分化程度显著相关(P<0.05),而HLA I类分子的表达下调百分率与患者的性别、年龄、肿瘤分级、淋巴结转移及分期均无相关性(P>0.05)。ccRCC组织中Livin的表达与HLA I类分子的表达亦无显著相关性(P>0.05)。结论:Livin、HLA I类分子表达异常参与了ccRCC的发生、发展过程,Livin可能成为ccRCC的一个重要预后指标和治疗靶点。
Objective: To investigate the expression and clinical significance of Livin and HLA class I in human clear cell renal cell carcinoma (ccRCC). Methods: 80 cases of patients who underwent radical nephrectomy who were admitted to the First Affiliated Hospital of Harbin Medical University from December 2007 to December 2011 were selected. 80 cases of ccRCC tissues and 10 cases of adjacent normal renal tissues were detected by immunohistochemistry Livin and HLA-I molecules expression, and analyze the relationship between the clinicopathological features of patients. Results: No positive expression of Livin was found in 10 cases of adjacent normal renal tissues, while the positive expression rate of HLA-I was 100%. The positive rates of Livin and HLA class I in the ccRCC tissues were 41 (51.25%) and 48 (60.00%), respectively. The positive rate of Livin was significantly lower than that of the normal group (P <0.05). The positive rate of Livin in ccRCC tissues was significantly correlated with lymph node metastasis and histological differentiation (P <0.05), while the percentage of down-regulated HLA class I molecules was not associated with gender, age, tumor grade, lymph node metastasis and staging (P> 0.05). There was no significant correlation between Livin expression and HLA class I expression in ccRCC tissues (P> 0.05). CONCLUSION: Livin and HLA class I molecules are abnormally involved in the development and progression of ccRCC. Livin may be an important prognostic indicator and therapeutic target for ccRCC.